Analysis of small nucleolar RNAs in sputum for lung cancer diagnosis

Oncotarget

Volumn 7, Issue 5, 2016, Pages 5131-5142

  Su, Jian ^a   Liao, Jeipi ^a   Gao, Lu ^a   Shen, Jun ^a   Guarnera, Maria A ^a   Zhan, Min ^a   Fang, HongBin ^a   Stass, Sanford A ^a   Jiang, Feng ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; Diagnosis; Lung cancer; snoRNAs; Sputum

Indexed keywords

BIOLOGICAL MARKER; SMALL NUCLEOLAR RNA; SNORD66; SNORD78; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; SPUTUM ANALYSIS; SPUTUM CYTODIAGNOSIS; CYTOLOGY; GENETICS; LUNG NEOPLASMS; SPUTUM;

AGED; BIOMARKERS, TUMOR; HUMANS; LUNG NEOPLASMS; RNA, SMALL NUCLEOLAR; SPUTUM;

EID: 84958093717     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4219     Document Type: Article

References (55)

1. Cancer Facts & Figures 2012. American Cancer Society (ACS). Journal of Consumer Health on the Internet. 2012; 16:366-367.
2. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM and Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365:395-409.
3. Patz EF, Jr., Pinsky P, Gatsonis C, Sicks JD, Kramer BS, Tammemagi MC, Chiles C, Black WC, Aberle DR. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med. 2014; 174:269-274.
4. Saccomanno G, Saunders RP, Archer VE, Auerbach O, Kuschner M and Beckler PA. Cancer of the lung: the cytology of sputum prior to the development of carcinoma. Acta Cytol. 1965, 9:413-423.
5. Thunnissen E, Belien JA, Kerr KM, Chung JH, Flieder DB, Noguchi M, Yatabe Y, Hwang DM, Lely RJ and Hartemink KJ. In compressed lung tissue microscopic sections of adenocarcinoma in situ may mimic papillary adenocarcinoma. Arch Pathol Lab Med. 2013; 137:1792-1797.
6. Mattick JS and Makunin IV. Non-coding RNA. Hum Mol Genet. 2006; 15 Spec No 1:R17-29.
7. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011; 12:861-874.
8. Deng G and Sui G. Noncoding RNA in oncogenesis: a new era of identifying key players. Int J Mol Sci. 2013; 14:18319-18349.
9. Sozzi G, Pastorino U and Croce CM. MicroRNAs and lung cancer: from markers to targets. Cell Cycle. 2011; 10:2045-2046.
10. Xing L, Su J, Guarnera MA, Zhang H, Cai L, Zhou R, Stass SA and Jiang F. Sputum microRNA biomarkers for identifying lung cancer in indeterminate solitary pulmonary nodules. Clin Cancer Res. 2015; 21:484-489.
11. Shen J, Liao J, Guarnera MA, Fang H, Cai L, Stass SA and Jiang F. Analysis of MicroRNAs in sputum to improve computed tomography for lung cancer diagnosis. J Thorac Oncol. 2014; 9:33-40.
12. Li N, Ma J, Guarnera MA, Fang H, Cai L and Jiang F. Digital PCR quantification of miRNAs in sputum for diagnosis of lung cancer. J Cancer Res Clin Oncol. 2014; 140:145-150.
13. Anjuman N, Li N, Guarnera M, Stass SA and Jiang F. Evaluation of lung flute in sputum samples for molecular analysis of lung cancer. Clin Transl Med. 2013; 2:15.
14. Yu L, Todd NW, Xing L, Xie Y, Zhang H, Liu Z, Fang H, Zhang J, Katz RL and Jiang F. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer. 2010; 127:2870-2878.
15. Xing L, Todd NW, Yu L, Fang H and Jiang F. Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod Pathol. 2010; 23:1157-1164.
16. Xie Y, Todd NW, Liu Z, Zhan M, Fang H, Peng H, Alattar M, Deepak J, Stass SA and Jiang F. Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer. 2010; 67:170-176.
17. Mannoor K, Shen J, Liao J, Liu Z and Jiang F. Small nucleolar RNA signatures of lung tumor-initiating cells. Mol Cancer. 2014; 13:104.
18. Mei Y, Clark D and Mao L. Novel dimensions of piRNAs in cancer. Cancer Lett. 2013; 336:46-52.
19. Williams GT and Farzaneh F. Are snoRNAs and snoRNA host genes new players in cancer? Nat Rev Cancer. 2012; 12:84-88.
20. Dong XY, Rodriguez C, Guo P, Sun X, Talbot JT, Zhou W, Petros J, Li Q, Vessella RL and Kibel AS. SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. Hum Mol Genet. 2008; 17:1031-1042.
21. Mannoor K, Liao J and Jiang F. Small nucleolar RNAs in cancer. Biochim Biophys Acta. 2012; 1826:121-128.
22. Mei YP, Liao JP, Shen J, Yu L, Liu BL, Liu L, Li RY, Ji L, Dorsey SG, Jiang ZR and Jiang F. Small nucleolar RNA 42 acts as an oncogene in lung tumorigenesis. Oncogene. 2012; 31:2794-2804.
23. Liao J, Yu L, Mei Y, Guarnera M, Shen J, Li R, Liu Z and Jiang F. Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer. Mol Cancer. 2010; 9:198.
24. Su H, Xu T, Ganapathy S, Shadfan M, Long M, Huang TH, Thompson I and Yuan ZM. Elevated snoRNA biogenesis is essential in breast cancer. Oncogene. 2014; 33:1348-1358.
25. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M and Yasui Y. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001; 93:1054-1061.
26. Gillaspie EA, Allen MS. Computed Tomographic Screening for Lung Cancer: The Mayo Clinic Experience. Thorac Surg Clin. 2015; 25:121-127.
27. Thorenoor N and Slaby O. Small nucleolar RNAs functioning and potential roles in cancer. Tumour Biol. 2015; 36:41-53.
28. Ravo M, Cordella A, Rinaldi A, Bruno G, Alexandrova E, Saggese P, Nassa G, Giurato G, Tarallo R, Marchese G et al. Small non-coding RNA deregulation in endometrial carcinogenesis. Oncotarget. 2015; 6:4677-4691.
29. Donsante A, Miller DG, Li Y, Vogler C, Brunt EM, Russell DW and Sands MS. AAV vector integration sites in mouse hepatocellular carcinoma. Science. 2007; 317:477.
30. Donsante A, Miller DG, Li Y, Vogler C, Brunt EM, Russell DW, Sands MS. AAV vector integration sites in mouse hepatocellular carcinoma. Science. 2007; 317:477.
31. Smith CM and Steitz JA. Classification of gas5 as a multismall-nucleolar-RNA (snoRNA) host gene and a member of the 5'-terminal oligopyrimidine gene family reveals common features of snoRNA host genes. Mol Cell Biol. 1998; 18:6897-6909.
32. Schneider C, King RM and Philipson L. Genes specifically expressed at growth arrest of mammalian cells. Cell. 1988; 54:787-793.
33. Mourtada-Maarabouni M, Pickard MR, Hedge VL, Farzaneh F and Williams GT. GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene. 2009; 28:195-208.
34. Kishore S and Stamm S. The snoRNA HBII-52 regulates alternative splicing of the serotonin receptor 2C. Science. 2006; 311:230-232.
35. Tanaka R, Satoh H, Moriyama M, Satoh K, Morishita Y, Yoshida S, Watanabe T, Nakamura Y and Mori S. Intronic U50 small-nucleolar-RNA (snoRNA) host gene of no protein-coding potential is mapped at the chromosome breakpoint t(3;6)(q27;q15) of human B-cell lymphoma. Genes Cells. 2000; 5:277-287.
36. Scott MS, Avolio F, Ono M, Lamond AI and Barton GJ. Human miRNA precursors with box H/ACA snoRNA features. PLoS Comput Biol. 2009; 5:e1000507.
37. Bell DW. Our changing view of the genomic landscape of cancer. J Pathol. 2010; 220:231-243.
38. Li R, Wang H, Bekele BN, Yin Z, Caraway NP, Katz RL, Stass SA and Jiang F. Identification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approach. Oncogene. 2006; 25:2628-2635.
39. Jiang F, Yin Z, Caraway NP, Li R and Katz RL. Genomic profiles in stage I primary non small cell lung cancer using comparative genomic hybridization analysis of cDNA microarrays. Neoplasia. 2004; 6:623-635.
40. Brody JS, Spira A. State of the art. Chronic obstructive pulmonary disease, inflammation, and lung cancer. Proc Am Thorac Soc. 2006; 3:535-537.
41. Henschke CI, Yankelevitz DF, Smith JP, Miettinen OS. Screening for lung cancer: the early lung cancer action approach. Lung Cancer. 2002; 35:143-148.
42. Henschke CI, Yankelevitz DF, Naidich DP, McCauley DI, McGuinness G, Libby DM, Smith JP, Pasmantier MW, Miettinen OS. CT screening for lung cancer: suspiciousness of nodules according to size on baseline scans. Radiology. 2004; 231:164-168.
43. Romeo MS, Sokolova IA, Morrison LE, Zeng C, Baron AE, Hirsch FR, Miller YE, Franklin WA, Varella-Garcia M. Chromosomal abnormalities in non-small cell lung carcinomas and in bronchial epithelia of high-risk smokers detected by multi-target interphase fluorescence in situ hybridization. J Mol Diagn. 2003; 5:103-112.
44. Varella-Garcia M, Kittelson J, Schulte AP, Vu KO, Wolf HJ, Zeng C, Hirsch FR, Byers T, Kennedy T, Miller YE et al. Multi-target interphase fluorescence in situ hybridization assay increases sensitivity of sputum cytology as a predictor of lung cancer. Cancer Detect Prev. 2004; 28:244-251.
45. Yu L, Shen J, Mannoor K, Guarnera M, Jiang F. Identification of ENO1 As a Potential Sputum Biomarker for Early-Stage Lung Cancer by Shotgun Proteomics. Clin Lung Cancer. 2014; 15:372-8.
46. Jiang F, Todd NW, Li R, Zhang H, Fang H, Stass SA. A panel of sputum-based genomic marker for early detection of lung cancer. Cancer Prev Res (Phila). 2010; 3:1571-1578.
47. Jiang F, Todd NW, Qiu Q, Liu Z, Katz RL, Stass SA. Combined genetic analysis of sputum and computed tomography for noninvasive diagnosis of non-small-cell lung cancer. Lung Cancer. 2009; 66:58-63.
48. Katz RL, Zaidi TM, Fernandez RL, Zhang J, He W, Acosta C, Daniely M, Madi L, Vargas MA, Dong Q et al. Automated detection of genetic abnormalities combined with cytology in sputum is a sensitive predictor of lung cancer. Mod Pathol. 2008; 21:950-960.
49. Qiu Q, Todd NW, Li R, Peng H, Liu Z, Yfantis HG, Katz RL, Stass SA, Jiang F. Magnetic enrichment of bronchial epithelial cells from sputum for lung cancer diagnosis. Cancer. 2008; 114:275-283.
50. Li R, Todd NW, Qiu Q, Fan T, Zhao RY, Rodgers WH, Fang HB, Katz RL, Stass SA, Jiang F. Genetic deletions in sputum as diagnostic markers for early detection of stage I non-small cell lung cancer. Clin Cancer Res. 2007; 13:482-487.
51. Machida EO, Brock MV, Hooker CM, Nakayama J, Ishida A, Amano J, Picchi MA, Belinsky SA, Herman JG, Taniguchi S et al. Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer. Cancer Res. 2006; 66:6210-6218.
52. Belinsky SA, Liechty KC, Gentry FD, Wolf HJ, Rogers J, Vu K, Haney J, Kennedy TC, Hirsch FR, Miller Y et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res. 2006; 66:3338-3344.
53. Obuchowski NA, Lieber ML, Wians FH, Jr. ROC curves in clinical chemistry: uses, misuses, and possible solutions. Clin Chem. 2004; 50:1118-1125.
54. Hosmer DW, Lemeshow S, Sturdivant RX. Applied Logistic Regression Third Edition Preface. Wiley Ser Probab St. 2013;Xiii-+.
55. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982; 143:29-36.